PubMed=8781117; DOI=10.1007/BF02602776
Gaugler B., Brouwenstijn N., Vantomme V., Szikora J.-P., van der Spek C.W., Patard J.-J., Boon T., Schrier P.I., van den Eynde B.J.
A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.
Immunogenetics 44:323-330(1996)

PubMed=8900424; DOI=10.1002/(SICI)1097-0215(19961009)68:2<177::AID-IJC6>3.0.CO;2-V
Brouwenstijn N., Gaugler B., Kruse K.M., van der Spek C.W., Mulder A., Osanto S., van den Eynde B.J., Schrier P.I.
Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Int. J. Cancer 68:177-182(1996)

PubMed=9413942; DOI=10.1038/bjc.1997.597; PMCID=PMC2228215
Brouwenstijn N., Slager E.H., Bakker A.B.H., Schreurs M.W.J., van der Spek C.W., Adema G.J., Schrier P.I., Figdor C.G.
Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage.
Br. J. Cancer 76:1562-1566(1997)

PubMed=10074909; DOI=10.1002/(SICI)1097-0215(19990315)80:6<799::AID-IJC1>3.0.CO;2-U
Dumas F., Gala J.-L., Berteau P., Brasseur F., Eschwege P., Paradis V., Lacour B., Philippe M., Loric S.
Molecular expression of PSMA mRNA and protein in primary renal tumors.
Int. J. Cancer 80:799-803(1999)

PubMed=11369790; DOI=10.1084/jem.193.10.1189; PMCID=PMC2193327
Probst-Kepper M., Stroobant V., Kridel R., Gaugler B., Landry C., Brasseur F., Cosyns J.-P., Weynand B., Boon T., van den Eynde B.J.
An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes.
J. Exp. Med. 193:1189-1198(2001)

PubMed=15585611; DOI=10.1158/1078-0432.CCR-04-0072
Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W., Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Clin. Cancer Res. 10:7799-7811(2004)

PubMed=18698046; DOI=10.1158/1078-0432.CCR-08-0028; PMCID=PMC2693478
Tykodi S.S., Fujii N., Vigneron N., Lu S.M., Mito J.K., Miranda M.X., Chou J., Voong L.N., Thompson J.A., Sandmaier B.M., Cresswell P., van den Eynde B.J., Riddell S.R., Warren E.H.
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
Clin. Cancer Res. 14:5260-5269(2008)